Safety and efficacy of rituximab in adults with relapsing-remitting multiple sclerosis: results of a phase II placebo-controlled, multicentre trial through 48 weeks

被引：0
|
作者：
Waubant, E.
Hauser, S.
Amold, D. L.
Vollmer, T.
Antel, J. P.
Fox, R.
Bar-Or, A.
Panzara, M.
Sarkar, N.
Agarwal, S.
Langer-Gould, A.
Smith, C.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] McGill Univ, Montreal, PQ H3A 2T5, Canada
[3] Barrow Neurol Clin, Phoenix, AZ USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Genentech Inc, San Francisco, CA 94080 USA
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [1] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen
    [J]. NEUROLOGY, 2011, 76 (09) : A545 - A545
  • [2] Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial
    Zhao, Y.
    Li, D. K. B.
    Riddehough, A.
    Traboulsee, A.
    Masterman, D.
    Gilberg, F.
    Kappos, L.
    Leppert, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 446 - 447
  • [3] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter A.
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen L.
    [J]. LANCET, 2011, 378 (9805): : 1779 - 1787
  • [4] A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS)
    Hauser, Stephen
    Waubant, Emmanuelle
    Arnold, Douglas
    Vollmer, Timothy
    Antel, Jack
    Fox, Robert
    Bar-Or, Amit
    Sarkar, Neena
    Langer-Gould, Annette
    Panzara, Michael
    Smith, Craig
    [J]. NEUROLOGY, 2007, 68 (12) : A99 - A100
  • [5] Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Yin, M.
    Leppert, D.
    Glanzman, R.
    Tinbergen, J.
    Hauser, S.
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 : 14 - 14
  • [6] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Yin, M.
    Leppert, D.
    Glanzmann, R.
    Tinbergen, J.
    Hauser, S. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S194 - S195
  • [7] Pharmacokinetics and pharmacodynamics of rituximab in adults with Relapsing Remitting Multiple Sclerosis (RRMS) in a 48-week phase 90 placebo-controlled, multicenter trial
    Bar-Or, Amit
    Waubant, Emmanuelle
    Ren, Song
    Sarkar, Neena
    Smith, Craig
    [J]. NEUROLOGY, 2008, 70 (11) : A226 - A227
  • [8] A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis
    Vollmer, T. L.
    Sorensen, P. Soelberg
    Arnold, D. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S507 - S508
  • [9] Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
    Calabresi, Peter A.
    Radue, Ernst-Wilhelm
    Goodin, Douglas
    Jeffery, Douglas
    Rammohan, Kottil W.
    Reder, Anthony T.
    Vollmer, Timothy
    Agius, Mark A.
    Kappos, Ludwig
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Lublin, Fred D.
    [J]. LANCET NEUROLOGY, 2014, 13 (06): : 545 - 556
  • [10] Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis A Randomized, Placebo-Controlled Trial
    Bellmann-Strobl, Judith
    Paul, Friedemann
    Wuerfel, Jens
    Doerr, Jan
    Infante-Duarte, Carmen
    Heidrich, Elmira
    Koertgen, Benedict
    Brandt, Alexander
    Pfuller, Caspar
    Radbruch, Helena
    Rust, Rebekka
    Siffrin, Volker
    Aktas, Orhan
    Heesen, Christoph
    Faiss, Juergen
    Hoffmann, Frank
    Lorenz, Mario
    Zimmermann, Benno
    Groppa, Sergiu
    Wernecke, Klaus-Dieter
    Zipp, Frauke
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):
12345